and sphingosine 1-phosphate (S1P) are two major sphingomyelin derivatives present at high levels in blood. The aim of the present work was to investigate whether S1P and SPH exert relevant actions in mouse skeletal muscle contractility and fatigue. Exogenous S1P and SPH administration caused a significant reduction of tension decline during fatigue of extensor digitorum longus muscle. Final tension after the fatiguing protocol was 40% higher than in untreated muscle. Interestingly, N,N-dimethylsphingosine, an inhibitor of SPH kinase (SK), abolished the effect of supplemented SPH but not that of S1P, suggesting that SPH acts through its conversion to S1P. Moreover, SPH was not effective in Ca 2ϩ -free solutions, in agreement with the hypothesis that SPH action is dependent on its conversion to S1P by the Ca 2ϩ -requiring enzyme SK. In contrast to SPH, S1P produced its positive effects on fatigue in Ca 2ϩ -free conditions, indicating that S1P action does not require Ca 2ϩ entry and most likely is receptor mediated. The effects of S1P could be ascribed in part to its ability to prevent the reduction (Ϫ20 mV) of action potential amplitude caused by fatigue. In conclusion, these results indicate that extracellular S1P has protective effects during the development of muscle fatigue and that the extracellular conversion of SPH to S1P may represent a rheostat mechanism to protect skeletal muscle from possible cytotoxic actions of SPH. sphingosine kinase; action potential; sphingosine
THE SPHINGOMYELIN SIGNALING PATHWAY exerts important biological actions in different cell types (25-27, 37, 43) . The receptor-mediated activation of sphingomyelinase sequentially generates different biologically active compounds, namely, ceramide, sphingosine (SPH), and sphingosine 1-phosphate (S1P). Ceramide activates pathways that regulate stress responses, cell senescence, and apoptosis (21) . The enzyme ceramidase converts ceramide to SPH, which can be phosphorylated to S1P by a specific kinase: sphingosine kinase (SK) (35) . SPH regulates the activity of intracellular targets (20) , while S1P shows both intracellular and extracellular actions, the latter by stimulating specific cell surface G protein-coupled receptors (25, 27, 37, 43) . SPH usually inhibits cell proliferation and promotes apoptosis, while S1P stimulates growth and protects against apoptosis (2, 37, 43) . Important to their actions is the considerable serum level of both SPH and S1P (9, 10, 13, 27, 47) . Because of the different and sometimes opposite roles of these lipids, great importance is attributed to the expression level and presence of the converting enzymes ceramidase and SK, whose activity may control the "sphingolipid rheostat" wherein the ratio of sphingolipids with opposing actions becomes important in determining cell fate (27, 37) .
Recent evidence shows that many of the signaling components of the sphingomyelin cascade are present in skeletal muscle (19, 40) . Data from rabbit, rat, and pig show that SPH is endogenous to skeletal muscle (6, 14, 39) . In fact, T-tubular membranes are rich in both SPH and the SPH precursor sphingomyelin (15, 39) , and T tubules express high levels of sphingomyelinase activity (19, 40) . Ceramide is elevated in fast-twitch glycolytic rat skeletal muscles and low in oxidative muscles (14) . Importantly, during prolonged exercise, sphingomyelinase activity of skeletal muscle increases, ceramide level decreases, and SPH level increases (15) , suggesting that the whole sphingomyelin pathway is activated in exercised muscles. SPH is reported to act on the ryanodine receptor, the sarcoplasmic reticulum (SR) Ca 2ϩ release channel (5, 6, 34, 38, 42) , and the T tubule dihydropyridine receptor (DHPR) voltage-dependent Ca 2ϩ channel, i.e., the protein complex responsible for the L-type Ca 2ϩ current in cardiac muscle cells (29, 44) . SPH is also known to regulate the activity of protein kinase C and related downstream pathways (20) ; thus it also may act in skeletal muscle, especially considering that this kinase is localized to the T-tubular membranes (41) . The level of S1P in resting skeletal muscle is estimated to be in the low nanomolar range (47) , but its possible role in contractility and fatigue has not been evaluated. S1P mobilizes Ca 2ϩ in C 2 C 12 myoblasts, apparently by activating membrane voltage-sensitive Ca 2ϩ channels and intracellular Ca 2ϩ release channels (18, 30) . The extracellular action of S1P occurs by activation of specific G protein-coupled cell surface receptors (25, 37, 43) , which have been described in skeletal muscle (4) . SK is also expressed in skeletal muscle extracellular surfaces (30) , suggesting that some of the SPH effects could be explained by SPH's enzymatic conversion to S1P. Consistent with this view is our recent demonstration that SPH released from cardiomyocytes is rapidly converted to S1P (7) .
Because both SPH and S1P are present at very high levels in the blood (9, 10, 13, 45) , muscle fibers are continuously bathed in elevated levels of the two lipids. Thus we decided to investigate the possible extracellular actions of SPH and S1P in skeletal muscle contractility and fatigue. Our results indicate that exogenous SPH and S1P administration makes the muscle more resistant to fatigue. Moreover, because pretreating muscle with SK inhibitors abolished the protective effect of SPH, it appears that SPH acts through its conversion to S1P and that S1P is responsible for the observed effects of SPH.
MATERIALS AND METHODS
All the experiments were conducted according to the Declaration of Helsinki regarding the treatment of animals during experimentation. The study was approved by the Ethics Committee of the Medical Faculty of the University of Padua. All efforts were made to minimize animal suffering and to use only the number of mice necessary to obtain reliable data.
Tension recording and fatigue protocols. Adult 3-month-old CD1 mice were used for these studies. Extensor digitorum longus (EDL) muscles were removed and placed in a bath containing Ringer physiological saline solution maintained at room temperature and containing 120 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl 2, 3.15 mM MgCl2, 1.3 mM NaH2PO4, 25 mM NaHCO3, 11 mM glucose, and 30 M D-tubocurarine, pH 7.2-7.4. The solution was continuously bubbled with 95% O 2-5% CO2 until used. For the experimental test, muscles were mounted in a vertical bath filled with 12 ml of the above physiological solution bubbled with 95% O 2-5% CO2 at 30°C. Muscles were electrically stimulated with supramaximal pulses (0.5-ms duration, 0.01 s Ϫ1 ) delivered using a Grass S44 electronic stimulator (Grass Instrument, Quincy, MA) through a stimulus isolation unit (Grass SIU5), and isometric force was recorded with a force transducer (Grass FT03). Muscle responses were recorded via an AT-MIO 16 AD card, and data were analyzed using a virtual instrument created with the LabView software program (National Instruments, Austin, TX) (11) . Muscles were stretched to the optimal length for twitch tension and equilibrated for 15 min at 30°C in the medium, to which either 5 M fatty acid-free bovine serum albumin (BSA) was added in control experiments; otherwise, the indicated compounds were added.
Before and after the incubation period, twitch and tetanic (150 Hz, 200 ms) tension levels were measured. Muscles were then subjected to a fatigue protocol consisting of a train of short tetani (150 Hz, 200 ms, 0.2/s) under the conditions described below. Recovery of muscle tetanic tension after administration of the fatigue protocol was followed for 30 min, with a single tetanus (150 Hz, 200 ms) delivered to muscles every 5 min. Recovery was recorded as the percentage of initial tension.
It is worth noting that we analyzed fatigue development only in selected muscles having about the same initial tetanic tension (N/g) to avoid the effects produced by different accumulation and depletion of metabolites during fatigue (17, 50) . The maximum tetanic tension, the final force (expressed as percentage of the initial force) and the time necessary for 50% tension decay (t 1/2) were measured.
Treatments. The fatigue experiments were performed according to the following protocols: 1) control condition, Ringer solution containing 5 M fatty acid-free BSA; 2) 1, 10, and 100 M SPH (Sigma); 3) 1, 10, and 20 M S1P (Avanti Polar Lipids); 4) SPH ϩ N,Ndimethylsphingosine (DMS, 20 M; Avanti Polar Lipids), an inhibitor of SPH kinase (46) that converts SPH to S1P; 5) 10 or 20 M DMS; 6) 0.25 M bis-indolylmaleimide (bis-IM; Sigma), a cellpermeable inhibitor of protein kinase C; 7) SPH ϩ bis-IM, 10 M SPH, and 0.25 M bis-IM; 8) S1P ϩ bis-IM, 10 M S1P, and 0.25 M bis-IM; 9) SPH/Ca 2ϩ -free Ringer solution, 10 M SPH in a Ca 2ϩ -free solution; and 10) S1P/Ca 2ϩ -free Ringer solution, 10 M S1P in a Ca 2ϩ -free solution. SPH, S1P, DMS, and bis-IM were dispersed by performing sonication on a solution of 5 mM fatty acid-free BSA and then storing it at Ϫ80°C until used. Before addition to the bath, SPH, DMS, and S1P were briefly sonicated and delivered to the physiological medium so that the final concentration of albumin was 5 M.
Electrophysiological analysis. Skeletal muscle fiber resting membrane potential (RMP) and directly evoked action potential (AP) were studied in control and fatigued fibers in the absence or presence of 10 M SPH or S1P using intracellular glass microelectrodes filled with 3 M KCl. EDL muscles were incubated for 30 min with SPH or S1P before the experiment was begun at 21 Ϯ 1°C. Direct extracellular stimulation was performed using two-needle Ag/AgCl electrodes with supramaximal electrical stimuli (130 -150 V, 0.1-ms duration) as described previously (32) . Intracellular recorded signals were sent to a preamplifier (WPI 705; World Precision Instruments) and then to a signal conditioner (CyberAmp; Axon Instruments-Molecular Devices, Union City, CA). The output signal from the conditioner was then fed to a digital oscilloscope (Tektronix 5022N; Tektronix, Richardson, TX). No more than a single AP was generally recorded from the same fiber, because muscle membrane was damaged during each stimulation by the relative movements of the recording electrode with respect to the contracting muscle. The maximal rate of AP rise was determined by calculating the first derivative of the digitized spike.
Determination of SPH levels by reverse-phase HPLC. SPH was determined using HPLC according to a previously described method (9) . Briefly, sphingolipids were extracted with butanol and derivatized with o-phthaldehyde (Molecular Probes, Eugene, OR). Samples were separated on a Hi-Pore Reversed Phase Column RP-318 (4.6 mm ϫ 25 cm; Bio-Rad, Hercules, CA) run on a Bio-Rad HPLC system equipped with a PerkinElmer fluorescence detector (excitation, 340 nm; emission, 455 nm). The solvent system was composed of methanol, glacial acetic acid, 1 M tetrabutylammonium dihydrogenphosphate, and nanopure water (82.9:1.5:0.9:14.7, vol/vol) run at 1.0 ml ⅐ min Ϫ1 . It is worth mentioning that the assay measures SPH content of the whole muscle and that it is not possible to evaluate the contribution of SPH derived from blood, smooth muscle, or endothelial cells. As a consequence, even though the enzymatic apparatus for SPH production has been demonstrated in skeletal muscle T tubules (15, 19, 39) , some of the muscle SPH could be generated by nonmuscle cells.
Membrane preparation and [ 3 H]ryanodine binding assay.
Heavy membrane fractions were purified from mouse hindlimb muscles as previously described (28) . Briefly, muscle homogenates were prepared in 10 mM HEPES, pH 7.4, and 20 mM KCl buffer, supplemented with the Complete protease inhibitor cocktail (Roche), and centrifuged at 650 g for 10 min. The myofibrillar sediment was reextracted twice in the same buffer. The three supernatants were then pooled and centrifuged at 120,000 g for 90 min. The total membrane fraction was resuspended in 0.3 M sucrose and 10 mM Tris ⅐ HCl, pH 7.4, and stored at Ϫ80°C.
SR-enriched membranes (at a protein concentration of 0.1 mg ⅐ ml Ϫ1 ) were incubated with 50 nM [ 3 H]ryanodine in 0.5 ml of 0.1 M KCl, 50 M CaCl 2, and 20 mM HEPES, pH 7.4, for 30 min at 37°C in the presence of various concentrations of SPH (5, 6, 38) . The sphingoid base was added to the medium assay as a DMSO solution, and the solute did not exceed 1% of total volume. Control experiments demonstrated that the vehicle had no effect on ryanodine binding. Bound 
Statistical analysis.
The force recorded during the fatigue protocol was normalized to the initial tension. Individual values are presented as means Ϯ SE. Means were compared using ANOVA, and significance was determined using the Kruskal-Wallis post hoc test. The statistical significance of SPH levels was determined using Student's t-test for unpaired samples. Differences were considered significant at P Ͻ 0.05.
RESULTS
Effects of the different treatments on twitch and tetanic tension levels. All treatments did not affect twitch properties and tetanic tension in the resting state (data not shown).
Effects of S1P and SPH on the development of fatigue. Because SPH and S1P are normally present at high levels in the blood of experimental animals and humans (9, 10, 13, 45), we hypothesized that they might affect contractility and/or fatigue. Thus we performed fatigue protocols in the presence of exogenously applied SPH and S1P. Normal development of fatigue induced by repeated brief contractions at 150 Hz in the EDL muscle occurred as a progressive decline of force output during the 6-min stimulation protocol (Fig. 1) , reaching 22.8 Ϯ 2.2% of initial tension value, whereas t 1/2 was 2.35 Ϯ 0.17 min (Table 1) . First, three concentrations of exogenous SPH were tested. In the presence of 1 and 10 M SPH, a marked slowing of force decline was observed ( Fig. 1 and Table 1 ). In contrast, the reduction of fatigue produced by 100 M SPH was not significant. Muscle recovery in the presence of SPH was similar to that of control EDL (Fig. 1) .
We then evaluated the effects of S1P on fatigue development. Similar to the findings with its metabolic precursor, SPH, S1P at 1 and 10 M caused a significant reduction of fatigue development (Fig. 2) as indicated by the substantial increase of both final force and t 1/2 with respect to controls ( Table 1) . As also observed with SPH, higher S1P levels (20 M) slightly but not significantly reduced fatigue development ( Table 1 ). The recovery of the muscles treated with S1P did not differ from that of controls.
Because SK activity has been detected on the extracellular side of cells (48), including skeletal muscle cells (30, 33) , we hypothesized that SPH could act indirectly on muscle fatigue development through its phosphorylation to S1P. To verify this hypothesis, the action of the SK inhibitor, DMS (46), was evaluated. The expected beneficial effects of SPH on fatigue parameters shown in Fig. 1 were completely abolished in the presence of DMS (Fig. 2) . In contrast, DMS (10 or 20 M) was without evident effects on muscle fatigue when it was delivered alone ( Table 1 ), suggesting that SPH produced during fatigue is not liberated into the extracellular medium. The recovery of the muscles treated with both SPH and DMS appeared to be slightly delayed (Fig. 2) .
Effects of bis-IM on the development of fatigue. To evaluate whether SPH administration could produce, at least in part, an intracellular action through its well-known inhibitory action on protein kinase C activity (20) , we tested the effect of another potent inhibitor of the kinase, bis-IM, on the development of EDL muscle fatigue. Bis-IM produced only a moderate but not significant effect on EDL fatigue development ( Fig. 3 and Table 1 ). The simultaneous presence of bis-IM and SPH did not change the effect produced by bis-IM alone, suggesting that SPH action on EDL fatigue is not mediated by protein kinase C. In contrast, bis-IM was not able to alter the positive effect of S1P (Table 1) .
Effects of S1P and SPH on the development of fatigue in Ca
2ϩ -free solution. Several workers have demonstrated that S1P not only mobilizes Ca 2ϩ from intracellular stores but also can facilitate entry of Ca 2ϩ from extracellular medium (24, 43 ). Accordingly, we tested the action of this sphingolipid on EDL muscle fatigue produced in Ca 2ϩ -free Ringer solution to evaluate whether S1P's actions on fatigability were dependent on extracellular Ca 2ϩ . As Fig. 4 shows, S1P maintained its beneficial effect on fatigue development in Ca 2ϩ -free solutions. The final force output and t 1/2 values were similar to those obtained in the presence of S1P in normal Ringer solution and significantly higher (P Ͻ 0.05) than those produced by fatigued control muscles (Table 1) . Surprisingly, the beneficial effects of SPH were completely abolished by the absence of extracellular Ca 2ϩ (Fig. 4) . The recovery was not significantly different from control values.
Effects of S1P and SPH on electrophysiological properties. We next evaluated whether S1P and SPH effects on fatigue development could be explained by the effects of sphingolipid mediators on the skeletal muscle AP. SPH is known to induce depolarization of cardiomyocytes, probably by acting on the DHPR (29, 44) . S1P also appears to influence skeletal muscle membrane potential (4) , an action that is in part receptor mediated. These data thus suggest another possible site of action of the sphingolipids during EDL muscle fatigue. Accordingly, skeletal muscle fiber RMP and directly evoked APs were studied in control and fatigued fibers in the absence or presence of either S1P or SPH (10 M). As previously reported by others (for review, see Ref. 17 ), fatigue caused a significant fall in RMP and a decrease in AP amplitude and maximum rate of rise (Table 2) . For muscles at rest, the addition of S1P or SPH did not affect the RMP or the AP amplitude, while the maximum rate of rise of the AP was decreased. Interestingly, the presence of S1P or SPH prevented the fatigue-induced decrease in AP amplitude, while it did not alter the maximum rate of AP rise (Table 2) .
Endogenous SPH levels of mouse EDL. Next, we determined the concentration of SPH using HPLC in mouse EDL muscles at rest and after fatigue. The resting level of SPH was 13.2 Ϯ 4.2 nmol/g fresh tissue (n ϭ 4), while fatigue caused a significant increase of endogenous SPH concentration to 28.0 Ϯ 3.2 nmol/g fresh tissue (n ϭ 4; P Ͻ 0.03), confirming previous observations that this lipid mediator is increased in fatigued rat muscles (14) . The skeletal muscle endogenous level of S1P at rest is reported to be at least one order of magnitude lower than that of SPH (47) .
Effects of SPH and S1P on [ 3 H]ryanodine binding. SPH is known to affect the ryanodine binding of both the cardiac and skeletal muscle isoforms of the ryanodine receptor Ca 2ϩ release channel from rabbit, dog, and pig SR preparations (5, 6, 12, 34, 38, 42) . However, it is not known whether SPH affects the ryanodine receptor from SR mouse membranes as it does in other species. Figure 5 shows that SPH is able to produce a dose-dependent inhibition of [ (31), these data indicate that SPH acts as an inhibitor of the channel. The SPH concentration able to inhibit 50% of ryanodine binding (IC 50 ) was ϳ18 M. As also reported by others (42), S1P was without appreciable effects on [ 3 H]ryanodine binding (Fig. 5) .
DISCUSSION
The present work shows that the exogenous administration of S1P and SPH individually caused the significant slowing of fatigue. However, our data show that SPH action depends on its conversion to S1P. Hence, this report is the first to suggest that S1P may exert beneficial effects on the promotion of fatigue resistance. Our data also show that both S1P and SPH exert positive actions by affecting membrane electrophysiological properties of muscle fibers in preventing the fatiguedependent drop in AP amplitude.
Because both SPH and S1P demonstrated positive effects on mouse muscle fatigue, we asked whether SPH's beneficial effects could be indirect and mediated by its conversion into S1P. This hypothesis was suggested by recent findings showing that SK activity could be detected on the extracellular surfaces of cells (48) , including skeletal muscle cells (30) . We recently reported that a substantial amount of SPH produced by cardiomyocytes is released into the extracellular medium and rapidly phosphorylated to S1P (7). In the current study, we discovered that when muscle fatigue was produced in the presence of the SK inhibitor, DMS, the effects produced by SPH were completely abolished. Additional support for a role of SK is the finding that SPH is not effective in retarding fatigue when muscles do not have Ca 2ϩ in the extracellular fluid. It is known that SK activity is dependent on Ca 2ϩ (27, 35) . We suggest that a "rheostat" mechanism operates in skeletal muscle cells as it does in other cell types (27, 37) whereby S1P is generated from SPH directly at the extracellular surfaces by a Ca 2ϩ -dependent SK localized in the muscle cell basement membrane as suggested by observations in C 2 C 12 myoblasts (30) .
An interesting result is that exogenously applied S1P had the same effect in either the presence or absence of external Ca 2ϩ , suggesting that S1P does not act by mobilizing extracellular Ca 2ϩ . It has consistently been reported that in skeletal muscle, exogenous S1P induces Ca 2ϩ transients independent of L-type channels (4) . Thus S1P appears to act on the extracellular side by activating cell surface receptors and downstream signaling pathways, leading to an overall beneficial effect on decreasing the development of fatigue. Normally, S1P produces important intracellular actions by activating specific cell surface G protein-coupled receptors (25, 43) , and it is important to note that skeletal muscle possesses these receptors (4). SK is activated by several signals (35, 37, 43) , among which is the depletion of endoplasmic reticulum Ca 2ϩ stores (24) and Ca 2ϩ mobilization (48) , events that are known to occur during sustained lowfrequency fatigue stimulation (1, 3, 17, 50) .
We also have investigated whether SPH may exert an intracellular action by modulating the activity of protein kinase C, a well-established target for SPH (20) . However, SPH does not seem to produce the positive effects on fatigue through inhibition of protein kinase C, because the moderate, nonsignificant action produced by the cell-permeable inhibitor of the kinase, bis-IM, was not augmented by the addition of SPH. The data presented herein do not exclude the possibility that exogenously added SPH may affect the closure of the ryanodine receptor, a very potent effect of SPH that is shown in Fig. 5 . Finally, bis-IM does not influence the effects of S1P on fatigue, suggesting that the signaling pathway activated by S1P does not include protein kinase C.
A possible target of S1P and SPH action could be found in the effects of the lipids on the AP. In fact, our results show that S1P and SPH were able to counteract the fatigue-dependent decrease in AP amplitude. The prolonged duration of AP produced by the two lipids likely results in an increase in the Values are means Ϯ SE. Numbers in parentheses refer to number of fibers and animals, respectively. Resting membrane potential (RMP), amplitude, and maximum rate of rise (MRR) of action potentials of single fibers in control and after 30 min of incubation in either 10 M SPH or 10 M S1P. *P Ͻ 0.05 vs. resting control values; †P Ͻ 0.05 vs. fatigued muscle control values. useful voltage-dependent SR Ca 2ϩ release, resulting in a beneficial effect of the lipids in the attempt to counteract the reduction of tension output. Moreover, because it has been shown that AP propagation into the T tubules is impaired during fatigue, causing poor activation of central myofibers (16) , the action of S1P and SPH in causing prolongation of the active state could have a beneficial result by favoring the recruitment of all contractile elements. It has consistently been demonstrated that SPH affects the electrophysiological properties of voltage-gated Na ϩ channels in isolated cardiac myocytes (44) by decreasing the maximum current carried (peak current) and increasing the opening state. This should result in a reduction of the AP maximum rate of rise and an increase in AP amplitude. Moreover, S1P has been demonstrated to favor the receptor-mediated activation of Cl Ϫ currents, resulting in the depolarization of keratinocytes (49) , and also to cause depolarization of oligodendrocytes (22) , while it did not have an effect on the L-type Ca 2ϩ currents in an insulinoma cell line (23) . The present work also shows that SPH is an endogenous component of mouse skeletal muscle, with concentrations similar to those reported in rabbit, rat, and pig skeletal muscle (5, 6, 12, 34, 38, 42) . Moreover, during sustained contractile activity, total endogenous levels of SPH increased in whole muscle homogenates. Similar results were obtained previously in rat skeletal muscle (14) . The major source of SPH in cells is sphingomyelin, which is sequentially hydrolyzed by sphingomyelinase and ceramidase to form ceramide and SPH, respectively. The rise in SPH levels (and subsequent S1P production by the kinase) during fatigue may be due to the activation of the lysosomal acid sphingomyelinase as a result of the decline in intracellular pH that accompanies fatigue (17, 51 ). An additional increase in the level of SPH could be the consequence of the stimulation of a neutral sphingomyelinase and cell surface-specific receptors by circulating TNF-␣, IFN-␥, and IL-1␤, known activators of the sphingomyelinase pathway that have been shown to increase during sustained exercise (8, 26 ; for review, see Ref. 36) . We also report that the endogenous SPH elevation may affect fatigue development by direct actions on the SR Ca 2ϩ release channel. It is known that SPH is an endogenous modulator of the ryanodine receptor channel (5, 6, 12, 34, 38, 42) , altering ryanodine binding to the receptor (5, 38, 42) and its gating properties at the single-channel level (34) . We hypothesized in the present study that the intracellular actions of SPH on coupling also may be mitigated by the rheostat mechanism hypothesized herein, whereby the SPH is converted to S1P, which is known to have no influence on the ryanodine receptor (42) .
In conclusion, present results indicate that SPH exerts a protective effect on the development of fatigue through mechanisms mostly accounted for by SPH's conversion into S1P. The protective effects of these important signaling lipids is most likely attributable to their actions on the skeletal muscle AP; however, the abundant presence of S1P receptors on the skeletal muscle sarcolemma (4) suggests that G protein-coupled receptors may mediate S1P actions. Our laboratory is currently investigating this possibility.
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